Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
Blood|October 2, 2014
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantationRichard F Schlenk, Sabine Kayser, Lars Bullinger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel AgentsFiroozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
American Journal of Hematology|November 28, 2024
Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMTThomas Luft, Luuk Gras, Linda Koster, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
Leukemia & Lymphoma|April 19, 2019
A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation<sup>.</sup>Eline M P Cremers, Theo de Witte, Liesbeth de Wreede, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2021
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) StudySarah Lawless, Giulia Sbianchi, Curly Morris, et al.
Science Translational Medicine|May 8, 2020
Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1Johanna M Eberhard, Mathieu Angin, Caroline Passaes, et al.
Bone Marrow Transplantation|July 26, 2020
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMTNico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, et al.
Blood Cancer Discovery|February 6, 2025
Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell LymphomaNora Liebers, Ariane Boumendil, Hervé Finel, et al.
Haematologica|December 28, 2019
Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantationEva Wagner-Drouet, Daniel Teschner, Christine Wolschke, et al.
Pageof 18